ATE397753T1 - Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung - Google Patents

Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung

Info

Publication number
ATE397753T1
ATE397753T1 AT03701036T AT03701036T ATE397753T1 AT E397753 T1 ATE397753 T1 AT E397753T1 AT 03701036 T AT03701036 T AT 03701036T AT 03701036 T AT03701036 T AT 03701036T AT E397753 T1 ATE397753 T1 AT E397753T1
Authority
AT
Austria
Prior art keywords
prophylactic
screening method
therapeutic substance
kidney disease
protein
Prior art date
Application number
AT03701036T
Other languages
English (en)
Inventor
Masakuni Noda
Takanori Matsuo
Hiroko Tsuge
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE397753T1 publication Critical patent/ATE397753T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03701036T 2002-01-10 2003-01-09 Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung ATE397753T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002003769 2002-01-10

Publications (1)

Publication Number Publication Date
ATE397753T1 true ATE397753T1 (de) 2008-06-15

Family

ID=19190917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03701036T ATE397753T1 (de) 2002-01-10 2003-01-09 Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung

Country Status (6)

Country Link
US (1) US20050069948A1 (de)
EP (1) EP1467207B1 (de)
AT (1) ATE397753T1 (de)
AU (1) AU2003202489A1 (de)
DE (1) DE60321443D1 (de)
WO (1) WO2003060516A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1560025A3 (de) * 2003-10-03 2011-09-07 F. Hoffmann-La Roche AG Marker spezifisch für Diabetes
US7763441B2 (en) 2006-03-13 2010-07-27 Wyeth Modulators of gluconeogenesis
CN102816214B (zh) * 2012-07-27 2014-08-13 中国人民解放军军事医学科学院生物工程研究所 乙型肝炎病毒HBx基因的人工转录因子及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206152A (en) * 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
AUPN855496A0 (en) * 1996-03-07 1996-04-04 Unisearch Limited Prevention of proliferation of vascular cells
PL345207A1 (en) * 1998-06-02 2001-12-03 Glaxo Group Ltd Gene therapy method
US6008048A (en) * 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
WO2001004356A1 (en) * 1999-07-12 2001-01-18 Gene Logic, Inc. Modulation of egr-1 and egr-2 in heart disease
AUPQ367699A0 (en) * 1999-10-26 1999-11-18 Unisearch Limited Treatment of cancer
EP1239039A4 (de) * 1999-12-17 2004-05-06 Takeda Chemical Industries Ltd Neues polypeptid und dafür kodierende dna
AU2001251242A1 (en) * 2000-03-31 2001-10-15 Brown University Reseach Foundation Methods and compositions for regulating memory consolidation

Also Published As

Publication number Publication date
EP1467207A4 (de) 2006-06-07
DE60321443D1 (de) 2008-07-17
EP1467207B1 (de) 2008-06-04
AU2003202489A1 (en) 2003-07-30
US20050069948A1 (en) 2005-03-31
WO2003060516A1 (en) 2003-07-24
EP1467207A1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
DE60333963D1 (de) Zytokin Ligand zur Behandlung von Asthma und Atemwegsüberreaktivität
DK1521774T3 (da) Trunkerede Tau-proteiner
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
DK1645631T3 (da) Neisseria antigener og præparater
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
CY1107146T1 (el) Μεθοδοι για προληψη και θεραπεια ασθενειας alzheimer (ad)
BR0316502A (pt) Compostos quìmicos
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE60237791D1 (de) Zytokinproteinfamilie
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE490979T1 (de) Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
ITTO20000674A0 (it) Composizioni a base di aminoacidi, atte al trattamento dell'insufficienza cardiaca.
ATE393170T1 (de) Humanisierter antikörper gegen fibroblastenwachstumsfaktor 8 und fragment des antikörpers
ATE441713T1 (de) Tumorantigenprotein und dessen verwendung
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
ATE405827T1 (de) Screening-verfahren
DE60234843D1 (de) Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
ATE556135T1 (de) Neues protein
WO2003022300A1 (en) Preventives/remedies for bone/joint diseases
ATE328082T1 (de) Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen
EP1566386A4 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
ATE465175T1 (de) Neuer proteinkomplex und anwendungen davon
ATE409747T1 (de) Mit wt1 interagierendes protein, wtip

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties